List of Excipients in Branded Drug CORTROSYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amphastar Pharmaceuticals Inc	CORTROSYN	cosyntropin	0548-5900	SODIUM CHLORIDE
A-S Medication Solutions	CORTROSYN	cosyntropin	50090-4547	SODIUM CHLORIDE
Medical Purchasing Solutions LLC	CORTROSYN	cosyntropin	71872-7318	SODIUM CHLORIDE

CORTROSYN Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

Cortrosyn is a synthetic cosyntropin injection used as an adrenocorticotropic hormone stimulation test. Its commercial opportunity is concentrated in product redesign, hospital workflow, shortage resilience, and differentiated sterile presentation rather than in conventional chronic-use volume. The most credible opportunities are a ready-to-use liquid, improved reconstitution, supply-secure packaging, and a development platform for cosyntropin alternatives.

What is Cortrosyn and how is it formulated?

Cortrosyn contains cosyntropin, a synthetic polypeptide corresponding to the first 24 amino acids of human adrenocorticotropic hormone. It is administered intravenously or intramuscularly to evaluate adrenal cortical function.[1]

The conventional presentation is a single-dose vial containing 0.25 mg of cosyntropin for reconstitution before administration. The labeled formulation includes mannitol. The reconstitution diluent is generally 0.9% sodium chloride injection, supplied separately or sourced by the healthcare provider depending on the presentation.[1]

Attribute	Cortrosyn profile
Active ingredient	Cosyntropin
Pharmacologic class	Adrenocorticotropic hormone analog
Primary use	ACTH stimulation testing
Common strength	0.25 mg per vial
Route	Intravenous or intramuscular
Dosage form	Sterile injectable, commonly lyophilized vial
Key excipient	Mannitol
Administration issue	Reconstitution before use
Commercial setting	Hospitals, endocrinology, diagnostic testing centers
Main product risk	Peptide stability, supply continuity, preparation burden

Mannitol has a conventional role as a bulking agent in lyophilized parenteral products. It can support cake formation and improve the physical handling of a freeze-dried peptide. The formulation must also control residual moisture, reconstitution time, particulate matter, pH, and peptide aggregation.

What excipient strategy best fits cosyntropin?

The most defensible strategy is to preserve a simple, low-excipient formulation unless a new presentation creates a material clinical or operational benefit.

Lyophilized vial strategy

For the existing vial format, mannitol provides a familiar and commercially efficient excipient platform. Development priorities would include:

• Consistent lyophilized cake appearance
• Rapid reconstitution with 0.9% sodium chloride
• Low residual moisture
• Control of oxidation, deamidation, aggregation, and adsorption
• Compatibility with glass vials, elastomer closures, and administration devices
• Stability across refrigerated and controlled room-temperature conditions

A formulation developer could evaluate alternative bulking or stabilizing systems, including sucrose, trehalose, glycine, or combinations of sugars and amino acids. These changes would require a strong justification because a simple diagnostic product has limited tolerance for added manufacturing complexity.

Ready-to-use liquid strategy

A ready-to-use liquid formulation has the highest commercial relevance. It could eliminate vial reconstitution, reduce preparation time, and lower the risk of dilution or handling errors.

The liquid formulation would need to address:

• Long-term peptide stability in solution
• Adsorption to container surfaces
• Protection against aggregation
• pH control
• Osmolality
• Sterility over shelf life
• Container-closure integrity
• Compatibility with syringes, needles, and infusion systems

Potential formulation tools include low concentrations of surfactants, amino acids, polyols, buffering agents, or sugars. Each excipient would increase regulatory and manufacturing complexity. A ready-to-use product would be commercially stronger if it retained a small excipient profile and used a prefilled syringe or a single-dose cartridge.

Preservative-free strategy

A preservative-free, single-dose presentation is likely to align with hospital injectable practice and minimize concerns about repeated exposure to antimicrobial preservatives. A multidose format could reduce packaging cost but would introduce sterility, in-use stability, and preservative-performance requirements.

For a diagnostic injection used intermittently, a multidose product has a weaker value proposition unless it materially reduces waste or improves access during supply disruptions.

What formulations are protected by patents?

Publicly available product information identifies formulation and manufacturing characteristics but does not establish a current, enforceable patent estate for the conventional Cortrosyn excipient composition. The principal commercial barriers are more likely to be manufacturing know-how, sterile filling capacity, validated peptide handling, regulatory approval, and reliable supply than broad composition-of-matter protection.

A new formulation could create patent opportunities in four areas:

1. Liquid cosyntropin formulations. Claims could cover defined pH ranges, excipient concentrations, stability periods, or reduced aggregation.
2. Lyophilized compositions. Claims could cover cosyntropin with specific bulking agents, stabilizers, residual moisture limits, or reconstitution performance.
3. Container-closure systems. Claims could cover prefilled syringes, cartridges, low-adsorption surfaces, or device-integrated delivery.
4. Manufacturing processes. Claims could cover peptide purification, sterile filtration, freeze-drying cycles, or methods that reduce degradation products.

Patent strength would depend on demonstrated technical effects. A claim that merely substitutes mannitol with another conventional excipient could face obviousness challenges. A formulation that provides a measured improvement in stability, reconstitution, or temperature tolerance would have a stronger basis.

When does Cortrosyn lose exclusivity?

Cortrosyn is an established product with a long commercial history. Its original regulatory exclusivity and any early composition patents are not the primary barriers to competition today. Current market protection depends on approved product quality, manufacturing capability, supply reliability, trademarks, and any later-listed patents covering a specific formulation, device, or use.

The relevant regulatory routes are:

• ANDA: Potential route for a product that matches the reference listed drug in active ingredient, strength, dosage form, route, and other applicable requirements.
• 505(b)(2): Potential route for a materially different formulation, presentation, or delivery system that relies partly on FDA findings for an existing cosyntropin product.
• NDA: Route for a clinically differentiated product or a product that cannot rely on an abbreviated pathway.

FDA’s Orange Book should be checked for current patent and exclusivity listings associated with the relevant Cortrosyn reference product. Patent listing status can change through product transfers, supplements, delistings, and new approvals.[2]

What is the Orange Book status of Cortrosyn?

The Orange Book identifies reference listed drugs, therapeutic equivalence evaluations, patents, and regulatory exclusivity where applicable.[2] Cortrosyn’s commercial position should be evaluated at the specific NDA and dosage-form level because cosyntropin products may have different sponsors, labels, and approval histories.

The key diligence points are:

Orange Book issue	Commercial relevance
Reference listed drug designation	Determines the product used for an ANDA comparison
Patent listings	Can trigger Paragraph IV certification or a 30-month stay
Exclusivity	Can delay certain abbreviated approvals
Therapeutic equivalence rating	Determines substitution potential
Sponsor and NDA ownership	Identifies the regulatory and commercial counterparty

No commercial strategy should assume that a cosyntropin product is unprotected merely because the active ingredient is old. A later formulation or device patent can create a narrower but relevant barrier.

Which companies are challenging Cortrosyn?

The competitive field includes branded cosyntropin, generic or abbreviated-approval entrants where available, and compounded or hospital-prepared alternatives. Competition is constrained by the small diagnostic market, sterile injectable requirements, and the need to maintain validated peptide potency.

Potential entrants are most likely to target one of three positions:

• Lower-cost generic vial
• Ready-to-use cosyntropin injection
• Supply-reliable alternative during shortages

The market does not have the same volume economics as high-use injectable drugs. A new entrant would need to avoid excessive development and manufacturing costs while securing hospital formulary acceptance.

What generic entry risks exist for Cortrosyn?

Generic entry risk is meaningful for the conventional vial because the product has an established clinical use and a relatively simple administration concept. The main barriers are technical rather than therapeutic:

• Peptide impurity profile
• Potency and assay comparability
• Sterility assurance
• Lyophilization reproducibility
• Reconstitution performance
• Container-closure compatibility
• Stability data
• Manufacturing-site qualification

A generic vial would likely exert price pressure without eliminating the market for a differentiated ready-to-use product. Hospitals may accept multiple suppliers if the product maintains uninterrupted availability and integrates into existing ACTH stimulation protocols.

How can excipients create commercial differentiation?

Excipient selection can support differentiation when it solves a measurable workflow or stability problem.

Faster reconstitution

A formulation that reconstitutes rapidly and consistently could reduce nursing and pharmacy preparation time. The commercial claim would be strongest if supported by comparative timing data, low foaming, minimal particulate generation, and stable potency after reconstitution.

Longer temperature tolerance

A product with improved excursion stability could reduce product loss in hospitals, ambulances, outpatient laboratories, and geographically dispersed facilities. This benefit would be commercially important if supported by formal stability data and clear labeling.

Reduced adsorption and aggregation

A low-adsorption formulation could improve dose consistency and reduce visible or subvisible particles. Surfactant use must be balanced against compatibility, safety, and extractables and leachables requirements.

Ready-to-use delivery

A prefilled syringe could remove the need for a separate diluent and transfer step. The value proposition includes lower preparation burden, fewer components, and more predictable dosing. Device development, human-factors validation, and combination-product requirements would increase cost.

What manufacturing and intellectual-property barriers matter?

The most important manufacturing barrier is reliable production of a sterile synthetic peptide with controlled impurities. Cosyntropin is shorter and less complex than a full biologic, but it remains sensitive to process conditions and storage.

Key know-how areas include:

• Peptide synthesis and cleavage
• Purification and impurity clearance
• Oxidation control
• Freeze-drying cycle design
• Sterile filtration and aseptic filling
• Container-closure selection
• In-process potency testing
• Stability-indicating analytical methods

A developer could protect process improvements through patents and trade secrets. Trade-secret protection may be more practical for manufacturing parameters that are difficult to reverse engineer from the finished vial.

What licensing deals and partnerships could support entry?

The most valuable partnerships would likely involve:

• Licensed cosyntropin drug substance
• Contract sterile manufacturing
• Lyophilization capacity
• Prefilled-syringe or cartridge technology
• Hospital distribution
• Diagnostic laboratory networks

A commercial agreement should allocate responsibility for peptide specifications, deviations, stability failures, shortage reporting, regulatory supplements, and change control. For a low-volume injectable, manufacturing economics can determine whether a licensing deal is viable.

No major public licensing transaction should be treated as a reliable market benchmark without confirming the transaction parties, rights granted, territory, milestones, and royalty terms through SEC filings, company announcements, or regulatory records.

How does Cortrosyn compare with potential reformulations?

Product concept	Main advantage	Main risk	Commercial outlook
Conventional lyophilized vial	Established format and lower formulation complexity	Reconstitution burden	Strongest low-cost entry target
Improved lyophilized vial	Faster reconstitution or better stability	Incremental differentiation	Moderate
Ready-to-use liquid vial	Removes reconstitution step	Solution stability and shelf life	High if stability is demonstrated
Prefilled syringe	Workflow and dosing convenience	Device cost and regulatory burden	High-value institutional niche
Multidose vial	Lower packaging waste	Preservative and sterility requirements	Limited
Alternative cosyntropin analog	Potentially broader clinical positioning	Clinical and regulatory development	Higher risk, larger opportunity

What revenue exposure exists?

Cortrosyn revenue is not a transparent proxy for the total cosyntropin market. Public disclosures may combine products, hospital medicines, and other specialty pharmaceuticals, making product-level revenue difficult to isolate.[3]

Commercial exposure should be modeled using:

• Annual ACTH stimulation test volume
• Average units per test
• Hospital and outpatient laboratory share
• Contract pricing
• Shortage-driven purchasing
• Generic discounting
• Ready-to-use conversion rate
• Waste reduction from single-dose packaging

The market is likely more attractive as a focused specialty injectable opportunity than as a high-volume blockbuster replacement. A supplier with existing sterile manufacturing and hospital distribution would have a structural advantage over a new entrant building infrastructure solely for cosyntropin.

What patent litigation affects Cortrosyn?

No broad, high-value patent litigation should be assumed without a current review of federal court dockets, FDA Orange Book records, and Paragraph IV notices. For a conventional cosyntropin product, litigation risk would most likely arise from:

• A later-listed formulation patent
• A device or prefilled-syringe patent
• A method-of-use patent covering a specific diagnostic protocol
• Manufacturing-process patents
• Trademark or trade-dress disputes

Method-of-use claims may have limited commercial value because ACTH stimulation testing is an established diagnostic application. Formulation and device claims are more likely to affect a differentiated entrant.

Key Takeaways

• Cortrosyn is a mature cosyntropin injectable with commercial value concentrated in diagnostic testing and hospital supply.
• Mannitol supports the conventional lyophilized-vial strategy, but a ready-to-use liquid would offer stronger workflow differentiation.
• The most important technical risks are peptide stability, aggregation, adsorption, reconstitution performance, sterility, and container compatibility.
• Generic entry risk is real for the conventional vial, while a stable liquid or prefilled syringe could occupy a higher-value niche.
• Patent opportunities are more credible for new formulations, devices, and manufacturing processes than for the legacy active ingredient.
• Manufacturing capacity and supply reliability may be more important competitive advantages than legacy patent protection.
• Product-level Cortrosyn revenue is not sufficiently transparent for a reliable standalone market-size estimate without verified company and channel data.
• Regulatory diligence should focus on the specific reference listed drug, NDA, Orange Book status, approval pathway, and any later-listed patents.

FAQs

Can mannitol be replaced in a cosyntropin formulation?

Yes, but substitution would require formulation development and regulatory support demonstrating acceptable stability, potency, sterility, reconstitution, and safety. Mannitol is difficult to displace commercially unless the replacement provides a measurable benefit.

Is a liquid cosyntropin product likely to require clinical trials?

The requirement depends on the formulation, route, dosage form, labeling, and regulatory pathway. A materially different liquid presentation may qualify for a 505(b)(2) approach, but FDA could require bridging or additional clinical evidence.

Could a cosyntropin prefilled syringe be sold as a generic?

Possibly, but the device, formulation, container, labeling, and reference-product requirements would determine the appropriate pathway. Device differences can create additional regulatory and patent issues.

What is the strongest excipient opportunity for Cortrosyn?

A low-complexity liquid formulation with extended stability, low adsorption, and rapid administration has the strongest commercial logic. A prefilled syringe could increase value if the market supports the added device cost.

Are biosimilar rules relevant to Cortrosyn?

Generally, no. Cosyntropin is a synthetic peptide drug rather than a conventional therapeutic biologic marketed through the biosimilar framework. The relevant pathway is more likely an ANDA, 505(b)(2), or full NDA, depending on product differences.

References

1. U.S. Food and Drug Administration. (n.d.). Cortrosyn (cosyntropin) injection prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. Amphastar Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.